Lilly + Ascidian – $1.9B RNA Exon Editing Deal

Summary Eli Lilly signed a collaboration with Ascidian worth up to $1.9B to develop in vivo RNA exon-editing therapies for inherited kidney diseases, validating RNA exon editing as a major emerging genetic medicine modality. What Happened The platform uses a single AAV to rewrite RNA…